Systemic lupus erythematosus (SLE) is a worldwide chronic autoimmune disease which
may affect every organ and tissue. Genetic predisposition, environmental triggers, and the …

Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of
self-tolerance and formation of nuclear autoantigens and immune complexes resulting in …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …

Caroline Gordon1, 2, 3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1, 3, Sue Brown4,
Ian N. Bruce5, 6, David D'Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10, 11 …

Background Systemic lupus erythematosus (SLE) is an autoimmune disease with a
prevalence of 36.7/100 000 in Germany and a female/male ratio of 4: 1. The clinical course …

Despite the continuing development of immunomodulatory agents and supportive care, the
prognosis associated with lupus nephritis (LN) has not improved substantially in the past …

Background: Antimalarial drugs (AMs), chloroquine (CQ) and hydroxychloroquine (HCQ),
are frequently withdrawn in patients with lupus with either severe or remitting disease …

Objective In 2016, the American Academy of Ophthalmology (AAO) changed the
recommended daily dose of hydroxychloroquine (HCQ) from 6.5 mg/kg to< 5 mg/kg …

Objective: In patients with systemic lupus erythematosus (SLE), hydroxychloroquine
prevents disease flares and damage accrual and facilitates the response to mycophenolate …